• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immuneering Corp Cl A (NQ: IMRX )

    1.130 -0.150 (-11.72%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 131,470
    Open 1.270
    Bid (Size) 1.110 (23)
    Ask (Size) 1.170 (2)
    Prev. Close 1.280
    Today's Range 1.110 - 1.290
    52wk Range 1.050 - 10.99
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Immuneering to Present at the Jefferies Global Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire

    Performance

    YTD
    -84.56%
    -84.56%
    1 Month
    -3.42%
    -3.42%
    3 Month
    -20.42%
    -20.42%
    6 Month
    -83.03%
    -83.03%
    1 Year
    -88.88%
    -88.88%

    More News

    Read More
    IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
    Via InvestorPlace
    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Recognizes Melanoma Awareness Month
    From Immuneering Corporation
    Via GlobeNewswire
    IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
    From Immuneering Corporation
    Via GlobeNewswire
    3 Stocks Insiders Are Buying That Analysts Love
    Via MarketBeat
    March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
    Via AB Newswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
    Via Benzinga
    Dow Falls Over 200 Points; Adobe Shares Plunge
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Crude Oil Edges Lower; US Consumer Sentiment Falls In March
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    What's Going On With Cancer-Focused Immuneering Stock On Thursday?
    Via Benzinga
    US Stocks Higher; Producer Prices Rise 0.6% In February
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
    From Immuneering Corporation
    Via GlobeNewswire
    Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
    Via FinancialNewsMedia
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.